{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T23:30:20Z","timestamp":1768519820151,"version":"3.49.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T00:00:00Z","timestamp":1730505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T00:00:00Z","timestamp":1730505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-024-03860-w","type":"journal-article","created":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T09:02:55Z","timestamp":1730538175000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Three-dimensional dynamics of mesothelin-targeted CAR.CIK lymphocytes against ovarian cancer peritoneal carcinomatosis"],"prefix":"10.1007","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2245-6810","authenticated-orcid":false,"given":"Federica","family":"Galvagno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Leuci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annamaria","family":"Massa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Donini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramona","family":"Rotolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9043-9014","authenticated-orcid":false,"given":"Sonia","family":"Capellero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Proment","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Letizia","family":"Vitali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea Maria","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7377-0888","authenticated-orcid":false,"given":"Valentina","family":"Tuninetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3294-8819","authenticated-orcid":false,"given":"Lorenzo","family":"D\u2019Ambrosio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5280-1411","authenticated-orcid":false,"given":"Alessandra","family":"Merlini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9787-5732","authenticated-orcid":false,"given":"Elisa","family":"Vigna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5444-6305","authenticated-orcid":false,"given":"Giorgio","family":"Valabrega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Primo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0096-1536","authenticated-orcid":false,"given":"Alberto","family":"Puliafito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7163-7071","authenticated-orcid":false,"given":"Dario","family":"Sangiolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,2]]},"reference":[{"issue":"2","key":"3860_CR1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1369\/0022155417742897","volume":"66","author":"JOAM van Baal","year":"2017","unstructured":"van Baal JOAM, van Noorden CJF, Nieuwland R, Van de Vijver KK, Sturk A, van Driel WJ et al (2017) Development of peritoneal carcinomatosis in epithelial ovarian cancer: a review. J Histochem Cytochem 66(2):67\u201383","journal-title":"J Histochem Cytochem"},{"key":"3860_CR2","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2020.31.e58","author":"L Burg","year":"2020","unstructured":"Burg L, Timmermans M, van der Aa M, Boll D, Rovers K, de Hingh I et al (2020) Incidence and predictors of peritoneal metastases of gynecological origin: a population-based study in the Netherlands. J Gynecol Oncol. https:\/\/doi.org\/10.3802\/jgo.2020.31.e58","journal-title":"J Gynecol Oncol"},{"issue":"1","key":"3860_CR3","doi-asserted-by":"crossref","first-page":"16061","DOI":"10.1038\/nrdp.2016.61","volume":"2","author":"UA Matulonis","year":"2016","unstructured":"Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY (2016) Ovarian cancer. Nat Rev Dis Primers 2(1):16061","journal-title":"Nat Rev Dis Primers"},{"key":"3860_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1125868","author":"S Breusa","year":"2023","unstructured":"Breusa S, Zilio S, Catania G, Bakrin N, Kryza D, Lollo G (2023) Localized chemotherapy approaches and advanced drug delivery strategies: a step forward in the treatment of peritoneal carcinomatosis from ovarian cancer. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2023.1125868","journal-title":"Front Oncol"},{"issue":"1","key":"3860_CR5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41572-021-00326-6","volume":"7","author":"D Cort\u00e9s-Guiral","year":"2021","unstructured":"Cort\u00e9s-Guiral D, H\u00fcbner M, Alyami M, Bhatt A, Ceelen W, Glehen O et al (2021) Primary and metastatic peritoneal surface malignancies. Nat Rev Dis Primers 7(1):91","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"3860_CR6","doi-asserted-by":"crossref","first-page":"379","DOI":"10.32604\/biocell.2024.047812","volume":"48","author":"L Ma","year":"2024","unstructured":"Ma L, Shao W, Zhu W (2024) Exploring the molecular mechanisms and potential therapeutic strategies of ferroptosis in ovarian cancer. Biocell 48(3):379\u2013386","journal-title":"Biocell"},{"issue":"3","key":"3860_CR7","doi-asserted-by":"crossref","first-page":"100149","DOI":"10.1016\/j.esmoop.2021.100149","volume":"6","author":"SI Kim","year":"2021","unstructured":"Kim SI, Kim JW (2021) Role of surgery and hyperthermic intraperitoneal chemotherapy in ovarian cancer\u2606. ESMO Open 6(3):100149","journal-title":"ESMO Open"},{"issue":"1","key":"3860_CR8","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13048-022-01020-1","volume":"15","author":"S Nag","year":"2022","unstructured":"Nag S, Aggarwal S, Rauthan A, Warrier N (2022) Maintenance therapy for newly diagnosed epithelial ovarian cancer\u2013 a review. J Ovar Res 15(1):88","journal-title":"J Ovar Res"},{"issue":"25","key":"3860_CR9","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Pothuri B, Vergote I, DePont CR, Graybill W, Mirza MR et al (2019) Niraparib in Patients with newly diagnosed advanced ovarian cancer. N Engl J Med 381(25):2391\u20132402","journal-title":"N Engl J Med"},{"issue":"25","key":"3860_CR10","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S, P\u00e9rol D, Gonz\u00e1lez-Mart\u00edn A, Berger R et al (2019) Olaparib plus Bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 381(25):2416\u20132428","journal-title":"N Engl J Med"},{"issue":"2","key":"3860_CR11","doi-asserted-by":"crossref","first-page":"358","DOI":"10.20517\/cdr.2023.13","volume":"6","author":"Y Won-Hee","year":"2023","unstructured":"Won-Hee Y, Anna D, Lawrence K (2023) Immune checkpoint inhibitors in ovarian cancer: Where do we go from here? Cancer Drug Resist 6(2):358\u2013377","journal-title":"Cancer Drug Resist"},{"issue":"41","key":"3860_CR12","doi-asserted-by":"crossref","first-page":"6979","DOI":"10.3748\/wjg.v19.i41.6979","volume":"19","author":"F Coccolini","year":"2013","unstructured":"Coccolini F, Gheza F, Lotti M, Virz\u00ec S, Iusco D, Ghermandi C et al (2013) Peritoneal carcinomatosis. World J Gastroenterol 19(41):6979\u20136994","journal-title":"World J Gastroenterol"},{"key":"3860_CR13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/978-3-540-30760-0_4","volume-title":"Advances in peritoneal surface oncology","author":"E de Bree","year":"2007","unstructured":"de Bree E, Tsiftsis DD (2007) Principles of perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis. In: Gonz\u00e1lez-Moreno S (ed) Advances in peritoneal surface oncology. Springer, Berlin Heidelberg, pp 39\u201351"},{"key":"3860_CR14","unstructured":"Center ULCC, Health NIo (2021) Phase I study of autologous CAR T-cells targeting the B7-H3 antigen in recurrent epithelial ovarian. https:\/\/classic.clinicaltrials.gov\/show\/NCT04670068"},{"key":"3860_CR15","unstructured":"Center CoHM, Institute NC (2022) Modified immune cells (TAG72-CAR T Cells) for the treatment of patients with platinum resistant epithelial ovarian cancer. https:\/\/classic.clinicaltrials.gov\/show\/NCT05225363"},{"key":"3860_CR16","unstructured":"Pennsylvania Uo, Health NIo (2017) Tmunity therapeutics awosoKP. CAR T cells in mesothelin expressing cancers. https:\/\/classic.clinicaltrials.gov\/show\/NCT03054298"},{"key":"3860_CR17","unstructured":"Center HLMC, Institute R (2022) Anixa Biosciences I. Infusion of autologous T cells engineered to target FSH receptor in recurrent ovarian cancer. https:\/\/classic.clinicaltrials.gov\/show\/NCT05316129"},{"issue":"1","key":"3860_CR18","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","volume":"22","author":"KM Maalej","year":"2023","unstructured":"Maalej KM, Merhi M, Inchakalody VP, Mestiri S, Alam M, Maccalli C et al (2023) CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer 22(1):20","journal-title":"Mol Cancer"},{"issue":"1","key":"3860_CR19","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","volume":"41","author":"K Pan","year":"2022","unstructured":"Pan K, Farrukh H, Chittepu VCSR, Xu H, Pan C-x, Zhu Z (2022) CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res 41(1):119","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"3860_CR20","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM (2021) CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J 11(4):69","journal-title":"Blood Cancer J"},{"issue":"2","key":"3860_CR21","first-page":"30","volume":"1","author":"B Yang","year":"2023","unstructured":"Yang B, Chen K, Liu X, Liu W, Ma Y, Tian X et al (2023) Advance in tumor immunotherapy: establishing a new paradigm for oncological treatment. Transl Surg Oncol 1(2):30\u201343","journal-title":"Transl Surg Oncol"},{"key":"3860_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.689697","author":"L Grunewald","year":"2021","unstructured":"Grunewald L, Lam T, Andersch L, Klaus A, Schwiebert S, Winkler A et al (2021) A reproducible bioprinted 3D tumor model serves as a preselection tool for CAR T cell therapy optimization. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2021.689697","journal-title":"Front Immunol"},{"key":"3860_CR23","doi-asserted-by":"crossref","first-page":"363","DOI":"10.7150\/jca.2.363","volume":"2","author":"D Sangiolo","year":"2011","unstructured":"Sangiolo D (2011) Cytokine induced killer cells as promising immunotherapy for solid tumors. J Cancer 2:363\u2013368","journal-title":"J Cancer"},{"issue":"13","key":"3860_CR24","first-page":"1673","volume":"21","author":"IG Schmidt-Wolf","year":"1993","unstructured":"Schmidt-Wolf IG, Lefterova P, Mehta BA, Fernandez LP, Huhn D, Blume KG et al (1993) Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 21(13):1673\u20131679","journal-title":"Exp Hematol"},{"key":"3860_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1229540","author":"E Cappuzzello","year":"2023","unstructured":"Cappuzzello E, Vigolo E, D\u2019Accardio G, Astori G, Rosato A, Sommaggio R (2023) How can Cytokine-induced killer cells overcome CAR-T cell limits. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2023.1229540","journal-title":"Front Immunol"},{"issue":"11","key":"3860_CR26","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.3390\/ijms20112839","volume":"20","author":"R Rotolo","year":"2019","unstructured":"Rotolo R, Leuci V, Donini C, Cykowska A, Gammaitoni L, Medico G et al (2019) CAR-based strategies beyond T Lymphocytes: integrative opportunities for cancer adoptive immunotherapy. Int J Mol Sci 20(11):2839","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3860_CR27","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1158\/2326-6066.CIR-19-0801","volume":"8","author":"SM Albelda","year":"2020","unstructured":"Albelda SM (2020) Tumor antigen heterogeneity: the \u201celephant in the room\u201d of adoptive T-cell therapy for solid tumors. Cancer Immunol Res 8(1):2","journal-title":"Cancer Immunol Res"},{"issue":"23","key":"3860_CR28","doi-asserted-by":"crossref","first-page":"6321","DOI":"10.1158\/1078-0432.CCR-20-0357","volume":"26","author":"V Leuci","year":"2020","unstructured":"Leuci V, Donini C, Grignani G, Rotolo R, Mesiano G, Fiorino E et al (2020) CSPG4-specific CARCIK lymphocytes as a novel therapy for the treatment of multiple soft-tissue sarcoma histotypes. Clin Cancer Res 26(23):6321\u20136334","journal-title":"Clin Cancer Res"},{"issue":"5","key":"3860_CR29","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1089\/hum.2017.207","volume":"29","author":"CF Magnani","year":"2018","unstructured":"Magnani CF, Mezzanotte C, Cappuzzello C, Bardini M, Tettamanti S, Fazio G et al (2018) Preclinical efficacy and safety of CD19CAR cytokine-induced killer cells transfected with sleeping beauty transposon for the treatment of acute lymphoblastic leukemia. Hum Gene Ther 29(5):602\u2013613","journal-title":"Hum Gene Ther"},{"issue":"1","key":"3860_CR30","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1186\/s13046-023-02884-x","volume":"42","author":"L Giraudo","year":"2023","unstructured":"Giraudo L, Cattaneo G, Gammaitoni L, Iaia I, Donini C, Massa A et al (2023) CSPG4 CAR-redirected cytokine induced killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma. J Exp Clin Cancer Res 42(1):310","journal-title":"J Exp Clin Cancer Res"},{"issue":"12","key":"3860_CR31","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s00262-015-1757-6","volume":"64","author":"X Ren","year":"2015","unstructured":"Ren X, Ma W, Lu H, Yuan L, An L, Wang X et al (2015) Modification of cytokine-induced killer cells with chimeric antigen receptors (CARs) enhances antitumor immunity to epidermal growth factor receptor (EGFR)-positive malignancies. Cancer Immunol Immunother 64(12):1517\u20131529","journal-title":"Cancer Immunol Immunother"},{"key":"3860_CR32","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.molimm.2017.03.017","volume":"85","author":"S Zuo","year":"2017","unstructured":"Zuo S, Wen Y, Panha H, Dai G, Wang L, Ren X et al (2017) Modification of cytokine-induced killer cells with folate receptor alpha (FR\u03b1)-specific chimeric antigen receptors enhances their antitumor immunity toward FR\u03b1-positive ovarian cancers. Mol Immunol 85:293\u2013304","journal-title":"Mol Immunol"},{"key":"3860_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.581468","author":"M Merker","year":"2020","unstructured":"Merker M, Wagner J, Kreyenberg H, Heim C, Moser LM, Wels WS et al (2020) ERBB2-CAR-engineered cytokine-induced killer cells exhibit both CAR-mediated and innate immunity against high-risk Rhabdomyosarcoma. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2020.581468","journal-title":"Front Immunol"},{"issue":"1","key":"3860_CR34","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1073\/pnas.93.1.136","volume":"93","author":"K Chang","year":"1996","unstructured":"Chang K, Pastan I (1996) Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci 93(1):136\u2013140","journal-title":"Proc Natl Acad Sci"},{"issue":"2","key":"3860_CR35","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1158\/2159-8290.CD-15-0583","volume":"6","author":"A Morello","year":"2016","unstructured":"Morello A, Sadelain M, Adusumilli PS (2016) Mesothelin-targeted CARs: driving T cells to solid tumors. Cancer Discov 6(2):133\u2013146","journal-title":"Cancer Discov"},{"issue":"6","key":"3860_CR36","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41389-020-00246-2","volume":"9","author":"R Coelho","year":"2020","unstructured":"Coelho R, Ricardo S, Amaral AL, Huang Y-L, Nunes M, Neves JP et al (2020) Regulation of invasion and peritoneal dissemination of ovarian cancer by mesothelin manipulation. Oncogenesis 9(6):61","journal-title":"Oncogenesis"},{"key":"3860_CR37","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0000000000001097","author":"S Weidemann","year":"2023","unstructured":"Weidemann S, Gorbokon N, Lennartz M, Hube-Magg C, Fraune C, Bernreuther C et al (2023) High homogeneity of mesothelin expression in primary and metastatic ovarian cancer. Appl Immunohistochem Mol Morphol. https:\/\/doi.org\/10.1097\/PAI.0000000000001097","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"1","key":"3860_CR38","doi-asserted-by":"crossref","first-page":"7002","DOI":"10.1038\/ncomms8002","volume":"6","author":"E Medico","year":"2015","unstructured":"Medico E, Russo M, Picco G, Cancelliere C, Valtorta E, Corti G et al (2015) The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets. Nat Commun 6(1):7002","journal-title":"Nat Commun"},{"issue":"1","key":"3860_CR39","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nbt1049","volume":"23","author":"M Amendola","year":"2005","unstructured":"Amendola M, Venneri MA, Biffi A, Vigna E, Naldini L (2005) Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters. Nat Biotechnol 23(1):108\u2013116","journal-title":"Nat Biotechnol"},{"key":"3860_CR40","first-page":"e3337","volume":"57","author":"HPH Naber","year":"2011","unstructured":"Naber HPH, Wiercinska E, Ten Dijke P, Van Laar T (2011) Van Laar T (2011) Spheroid Assay to Measure TGF-\u03b2-induced Invasion. JoVE 57:e3337","journal-title":"JoVE"},{"key":"3860_CR41","doi-asserted-by":"crossref","first-page":"e56554","DOI":"10.7554\/eLife.56554","volume":"9","author":"JL Galeano Ni\u00f1o","year":"2020","unstructured":"Galeano Ni\u00f1o JL, Pageon SV, Tay SS, Colakoglu F, Kempe D, Hywood J et al (2020) Cytotoxic T cells swarm by homotypic chemokine signalling. Elife 9:e56554","journal-title":"Elife"},{"issue":"1","key":"3860_CR42","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1038\/s41467-022-30575-2","volume":"13","author":"G Ronteix","year":"2022","unstructured":"Ronteix G, Jain S, Angely C, Cazaux M, Khazen R, Bousso P et al (2022) High resolution microfluidic assay and probabilistic modeling reveal cooperation between T cells in tumor killing. Nat Commun 13(1):3111","journal-title":"Nat Commun"},{"issue":"5","key":"3860_CR43","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/cgt.2016.14","volume":"23","author":"SC Katz","year":"2016","unstructured":"Katz SC, Point GR, Cunetta M, Thorn M, Guha P, Espat NJ et al (2016) Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery. Cancer Gene Ther 23(5):142\u2013148","journal-title":"Cancer Gene Ther"},{"issue":"8","key":"3860_CR44","doi-asserted-by":"crossref","first-page":"13545","DOI":"10.18632\/oncotarget.14592","volume":"8","author":"W Xia Ang","year":"2017","unstructured":"Xia Ang W, Li Z, Chi Z, Du S-H, Chen C, Tay JCK et al (2017) Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis. Oncotarget 8(8):13545","journal-title":"Oncotarget"},{"issue":"11","key":"3860_CR45","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","volume":"11","author":"PS Adusumilli","year":"2021","unstructured":"Adusumilli PS, Zauderer MG, Rivi\u00e8re I, Solomon SB, Rusch VW, O\u2019Cearbhaill RE et al (2021) A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the Anti\u2013PD-1 agent Pembrolizumab. Cancer Discov 11(11):2748\u20132763","journal-title":"Cancer Discov"},{"issue":"14","key":"3860_CR46","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1158\/1078-0432.CCR-14-1421","volume":"21","author":"SC Katz","year":"2015","unstructured":"Katz SC, Burga RA, McCormack E, Wang LJ, Mooring W, Point GR et al (2015) Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases. Clin Cancer Res 21(14):3149\u20133159","journal-title":"Clin Cancer Res"},{"key":"3860_CR47","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2023.0324","author":"Y Guo","year":"2023","unstructured":"Guo Y, Tong C, Wu Z, Lu Y, Wang Y, Han W (2023) Reciprocal activation of antigen-presenting cells and CAR T cells triggers a widespread endogenous anti-tumor immune response through sustained high-level IFN\u03b3 production. Cancer Biol Med. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2023.0324","journal-title":"Cancer Biol Med"},{"issue":"365","key":"3860_CR48","first-page":"265","volume":"12","author":"X Wang","year":"2023","unstructured":"Wang X, Qiu W, Liu H, He M, He W, Li Z et al (2023) The inducible secreting TLR5 agonist, CBLB502, enhances the anti-tumor activity of CAR133-NK92 cells in colorectal cancer. Cancer Biol Med 12(365):265","journal-title":"Cancer Biol Med"},{"issue":"11","key":"3860_CR49","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1016\/j.ymthe.2018.09.008","volume":"26","author":"C DeSelm","year":"2018","unstructured":"DeSelm C, Palomba ML, Yahalom J, Hamieh M, Eyquem J, Rajasekhar VK et al (2018) Low-dose radiation conditioning enables CAR T cells to mitigate antigen escape. Mol Ther 26(11):2542\u20132552","journal-title":"Mol Ther"},{"issue":"3","key":"3860_CR50","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1158\/2159-8290.CD-20-0756","volume":"11","author":"R Upadhyay","year":"2021","unstructured":"Upadhyay R, Boiarsky JA, Pantsulaia G, Svensson-Arvelund J, Lin MJ, Wroblewska A et al (2021) A critical role for fas-mediated off-target tumor killing in T-cell immunotherapy. Cancer Discov 11(3):599\u2013613","journal-title":"Cancer Discov"},{"issue":"2","key":"3860_CR51","doi-asserted-by":"crossref","first-page":"e005691","DOI":"10.1136\/jitc-2022-005691","volume":"11","author":"S Esther","year":"2023","unstructured":"Esther S, Thomas P, Ibrahim E-S, Ying Z, Rui H, Alina M et al (2023) Tuned activation of MSLN-CAR T cells induces superior antitumor responses in ovarian cancer models. J Immunother Cancer 11(2):e005691","journal-title":"J Immunother Cancer"},{"issue":"3","key":"3860_CR52","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/mt.2011.256","volume":"20","author":"E Lanitis","year":"2012","unstructured":"Lanitis E, Poussin M, Hagemann IS, Coukos G, Sandaltzopoulos R, Scholler N et al (2012) Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor. Mol Ther 20(3):633\u2013643","journal-title":"Mol Ther"},{"issue":"9","key":"3860_CR53","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/cas.12987","volume":"107","author":"S Kim","year":"2016","unstructured":"Kim S, Kim B, Song YS (2016) Ascites modulates cancer cell behavior, contributing to tumor heterogeneity in ovarian cancer. Cancer Sci 107(9):1173\u20131178","journal-title":"Cancer Sci"},{"issue":"1","key":"3860_CR54","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s13046-023-02798-8","volume":"42","author":"A Hrvat","year":"2023","unstructured":"Hrvat A, Schmidt M, Wagner B, Zwanziger D, Kimmig R, Volbracht L et al (2023) Electrolyte imbalance causes suppression of NK and T cell effector function in malignant ascites. J Exp Clin Cancer Res 42(1):235","journal-title":"J Exp Clin Cancer Res"},{"issue":"12","key":"3860_CR55","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.32604\/biocell.2023.043084","volume":"47","author":"C Chen","year":"2023","unstructured":"Chen C, Leng X, Zhang YU, Hu J, Wei D, Wang P et al (2023) Effects of platelets on characteristics of lymphocytes cultured in vitro and optimization of adoptive immunotherapy. Biocell 47(12):2661\u20132669","journal-title":"Biocell"},{"issue":"5","key":"3860_CR56","doi-asserted-by":"crossref","first-page":"e006509","DOI":"10.1136\/jitc-2022-006509","volume":"11","author":"DRE Ranoa","year":"2023","unstructured":"Ranoa DRE, Sharma P, Schane CP, Lewis AN, Valdez E, Marada VVVR et al (2023) Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model. J Immunother Cancer 11(5):e006509","journal-title":"J Immunother Cancer"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03860-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-024-03860-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03860-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T17:49:54Z","timestamp":1738259394000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-024-03860-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,2]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["3860"],"URL":"https:\/\/doi.org\/10.1007\/s00262-024-03860-w","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,2]]},"assertion":[{"value":"6 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Peripheral blood mononuclear cells of patients with advanced stage tumors were collected at Candiolo Cancer Institute and San Luigi Hospital, after releasing written informed consent according to internal Institutional Review Board (IRB)-approved protocols (no. 225\/2015; no. 125\/2022), per the Declaration of Helsinki guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All the authors gave consent for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"6"}}